The Buxton Helmsley Group (BHG), which holds a short position in Assertio Holdings (NASDAQ: ASRT), has released evidence supporting allegations of product-related fraud at Spectrum Pharmaceuticals, now owned by Assertio. The evidence includes a memo showing requests to delete adverse event data and audit reports revealing major discrepancies in clinical trial data. BHG has filed a whistleblower complaint with the SEC and calls on Assertio's board to release their full investigation report and documentation of communication with whistleblowers. BHG claims Assertio's recent denial fails to address specific allegations, including alleged 'hush money' offers to whistleblowers.

Positive

• None.

Negative

• Evidence of alleged product-related fraud at Spectrum Pharmaceuticals
• Documentation showing requests to delete adverse event data
• Major discrepancies found in clinical trial data
• Inadequate training of clinical trial staff reported
• Whistleblower complaint filed with SEC
• Questions raised about due diligence in Spectrum acquisition

Insights

The allegations of clinical trial data manipulation and adverse event deletion at Spectrum Pharmaceuticals (now owned by Assertio) represent serious regulatory concerns. The released evidence, including audit reports showing "Major" discrepancies and alleged attempts to delete adverse event data, could trigger significant FDA scrutiny and potential SEC investigations. This poses substantial risks including:

• Potential regulatory enforcement...

Read Full Story: https://news.google.com/rss/articles/CBMitwFBVV95cUxNRWVxVW9ScmlrNHBqcG9nbHJq...